Ödén Jakob, Toma-Dasu Iuliana, Eriksson Kjell, Flejmer Anna Maria, Dasu Alexandru
a Department of Physics, Medical Radiation Physics , Stockholm University , Stockholm , Sweden.
b RaySearch Laboratories , Stockholm , Sweden.
Acta Oncol. 2017 Nov;56(11):1428-1436. doi: 10.1080/0284186X.2017.1348625. Epub 2017 Aug 22.
Proton breast radiotherapy has been suggested to improve target coverage as well as reduce cardiopulmonary and integral dose compared with photon therapy. This study aims to assess this potential when accounting for breathing motion and a variable relative biological effectiveness (RBE).
Photon and robustly optimized proton plans were generated to deliver 50 Gy (RBE) in 25 fractions (RBE = 1.1) to the CTV (whole left breast) for 12 patients. The plan evaluation was performed using the constant RBE and a variable RBE model. Robustness against breathing motion, setup, range and RBE uncertainties was analyzed using CT data obtained at free-breathing, breath-hold-at-inhalation and breath-hold-at-exhalation.
All photon and proton plans (RBE = 1.1) met the clinical goals. The variable RBE model predicted an average RBE of 1.18 for the CTVs (range 1.14-1.21) and even higher RBEs in organs at risk (OARs). However, the dosimetric impact of this latter aspect was minor due to low OAR doses. The normal tissue complication probability (NTCP) for the lungs was low for all patients (<1%), and similar for photons and protons. The proton plans were generally considered robust for all patients. However, in the most extreme scenarios, the lowest dose received by 98% of the CTV dropped from 96 to 99% of the prescribed dose to around 92-94% for both protons and photons. Including RBE uncertainties in the robustness analysis resulted in substantially higher worst-case OAR doses.
Breathing motion seems to have a minor effect on the plan quality for breast cancer. The variable RBE might impact the potential benefit of protons, but could probably be neglected in most cases where the physical OAR doses are low. However, to be able to identify outlier cases at risk for high OAR doses, the biological evaluation of proton plans taking into account the variable RBE is recommended.
与光子治疗相比,质子乳腺放疗被认为可改善靶区覆盖并降低心肺剂量和积分剂量。本研究旨在评估在考虑呼吸运动和可变相对生物效应(RBE)时的这种潜力。
为12例患者生成光子和稳健优化的质子计划,以25次分割(RBE = 1.1)向CTV(整个左乳)给予50 Gy(RBE)。使用恒定RBE和可变RBE模型进行计划评估。利用自由呼吸、吸气屏气和呼气屏气时获得的CT数据分析对呼吸运动、摆位、射程和RBE不确定性的稳健性。
所有光子和质子计划(RBE = 1.1)均达到临床目标。可变RBE模型预测CTV的平均RBE为1.18(范围1.14 - 1.21),在危及器官(OAR)中RBE甚至更高。然而,由于OAR剂量较低,后一方面的剂量学影响较小。所有患者肺部的正常组织并发症概率(NTCP)较低(<1%),光子和质子的情况相似。质子计划通常被认为对所有患者都具有稳健性。然而,在最极端的情况下,CTV中98%接受的最低剂量从规定剂量的96%至99%降至质子和光子均约为92% - 94%。在稳健性分析中纳入RBE不确定性导致最坏情况下的OAR剂量大幅增加。
呼吸运动似乎对乳腺癌计划质量影响较小。可变RBE可能会影响质子治疗的潜在益处,但在大多数物理OAR剂量较低的情况下可能可以忽略。然而,为了能够识别出OAR高剂量风险的异常病例,建议对考虑可变RBE的质子计划进行生物学评估。